Insights
The Placebo response in drug development Part 3: Parkinson’s disease
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by both motor and non-motor features. The disease has a significant clinical impact on patients, families, and caregivers through its progressive degenerative effects on mobility and muscle control.
Read More
The placebo response in drug development. Part 2: Osteoarthritis
Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more common than rheumatoid arthritis (RA).
Read More
Are clinical trials patients’ reactions to crisis related to their personality? Application to the COVID-19 pandemic.
Not only are patient visits to clinical sites more difficult (or impossible), patients are also dealing with uncertainty, stress and anxiety. While keeping ongoing trials running is a top objective for many, understanding how this myriad of factors will affect trial data is paramount.
Read More
Data Integrity in GCP environment
As clinical trials become more complex, are conducted at more sites with multiple vendors (clinical sites, CROs, e-PRO, data management vendors, etc.), properly protecting data integrity becomes increasingly critical.
Read More
The Placebo response in drug development. Part 1: Rheumatoid Arthritis
Evidence has accumulated in recent years that the placebo response is a significant issue in evaluating efficacy of drugs for rheumatoid arthritis (RA). RA is a chronic disease characterized by inflammatory synovitis and progressive joint destruction.
Read More
The Opioid Crisis in the US: Fueling the Next Wave of Drug Development for Chronic Pain
While the opioid crisis may be creating opportunity for development of novel therapies to treat chronic pain, drug development in this area has historically struggled. According to a BIO report released in 2018, only two novel NCEs were approved for pain indications from 2007-2017 while other analgesia approvals during this period were reformulations of existing compounds or drugs with approval history prior to 2007.
Read More